

share
Adipiodone, Dimeglumine Salt CAS NO 3521-84-4
Unit Price:
CAS No.:3521-84-4
Grade:Pharmacy Grade
Content:99.9%
Brand:Customizable
Packaging:Customizable
Description
Adipiodone, Dimeglumine Salt is a diagnostic contrast agent salt, specifically formulated for enhanced stability and solubility in aqueous media. This compound is critical for providing clear radiographic imaging in medical diagnostics, ensuring reliable and safe visualization of internal structures. It is primarily required by pharmaceutical manufacturers and diagnostic imaging centers for the production of injectable contrast media.
Application
- X-ray Contrast Media: Key active pharmaceutical ingredient (API) in formulations for cholecystography (imaging of the gallbladder and biliary tract).
- Diagnostic Agent Synthesis: Serves as a crucial intermediate or final salt form in the synthesis of specialized iodinated contrast agents.
- Pharmaceutical Research: Used in R&D for developing new diagnostic formulations and studying pharmacokinetics.
- Veterinary Diagnostics: Applied in contrast imaging procedures for animals in veterinary medicine.
Basic Information
| Product Name | Adipiodone, Dimeglumine Salt |
| CAS No. | 3521-84-4 |
| Molecular Formula | C20H28I4N4O10 • 2(C7H17NO5) |
| Molecular Weight | 1530.18 g/mol (approx.) |
| Synonyms | Adipiodone Meglumine; Iodipamide Meglumine; Meglumine Iodipamide; Biligrafin; Cholografin; Iodipamide Methylglucamine; 3,3'-(Adipoyldiimino)bis[2,4,6-triiodobenzoic acid] compound with 1-deoxy-1-(methylamino)-D-glucitol (2:1); Bilivistan |
| EINECS | Contact for details |
Quality Control
Our Adipiodone, Dimeglumine Salt is manufactured under strict quality systems. Each batch is tested to ensure it meets high-purity standards suitable for pharmaceutical applications. A comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles is provided with every shipment to guarantee traceability and compliance.
Storage
Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept in a dry environment to prevent degradation.
Specification
| Item | Specification |
|---|---|
| Appearance | White to off-white powder |
| Identification (IR) | Conforms to reference spectrum |
| Assay (HPLC) | 98.0% - 102.0% (on anhydrous basis) |
| Water Content (KF) | ≤ 5.0 % |
| Heavy Metals | ≤ 20 ppm |
| Residue on Ignition | ≤ 0.1 % |
| Related Substances (HPLC) | Total impurities ≤ 2.0% Any single impurity ≤ 1.0% |
Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.
Hot Related Products


Diatrizoate Sodium CAS NO 737-31-5


Iobitridol CAS NO 136949-58-1


Indocyanine Green CAS NO 3599-32-4


Meglumine CAS NO 6284-40-8


Diatrizoic Acid CAS NO 117-96-4


Dimethiodal Sodium CAS NO 124-88-9


Methiodal Sodium CAS NO 126-31-8


Sodium Diprotrizoate CAS NO 129-57-7


Sodium Acetrizoate CAS NO 129-63-5


Meglumine Diatrizoate CAS NO 131-49-7


Ipodate Calcium (200 Mg) CAS NO 1151-11-7


Ipodate Sodium CAS NO 1221-56-3


Sodium 3-(Acetylamino)-2,4,6-Triiodo-5-[(Methylamino)Carbonyl]Benzoate CAS NO 1225-20-3


Bunamiodyl CAS NO 1233-53-0


3-[[n-(3-Amino-2,4,6-Triiodophenyl)-n-Methylamino]Carbonyl]Propionic Acid CAS NO 1221-05-2


3-[3-(Carbamoylmethyl)-2,4,6-Triiodo-Phenyl]Propanoic Acid CAS NO 1456-51-5


Ioprocemic Acid CAS NO 1456-52-6


Sodium 4-(4-Hydroxy-3-Iodophenoxy)-3,5-Diiodophenylacetate CAS NO 1477-04-9


Hydroxyamphetamine CAS NO 1518-86-1


Succinic Acid Mono-3-Amino-2,4,6-Triiodo-n-Ethylanilide CAS NO 1634-73-7
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.






